Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: A minor role of breast cancer resistance protein

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 1, 2005, Pages 44-52

  Lee, Young Joo ^a   Kusuhara, Hiroyuki ^a   Jonker, Johan W ^b   Schinkel, Alfred H ^b   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; ELACRIDAR; GLYCOPROTEIN P; MITOXANTRONE; PRASTERONE SULFATE;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN PERFUSION; CONTROLLED STUDY; DRUG TRANSPORT; DRUG UPTAKE; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; WILD TYPE;

ACRIDINES; ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DEHYDROEPIANDROSTERONE SULFATE; DRUG INTERACTIONS; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MITOXANTRONE; P-GLYCOPROTEIN; TETRAHYDROISOQUINOLINES; TRITIUM;

EID: 11844267237     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.073320     Document Type: Article

References (40)

1. Allen JD, Brinkhuis RF, Wijnholds J, and Schinkel AH (1999) The mouse Bcrp1/ Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237-4241.
2. Asaba H, Hosoya K, Takanaga H, Ohtsuki S, Tamura E, Takizawa T, and Terasaki T (2000) Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2. J Neurochem 75:1907-1916.
3. Ball HJ, McParland B, Driussi C, and Hunt NH (2002) Isolating vessels from the mouse brain for gene expression analysis using laser capture microdissection. Brain Res Brain Res Protoc 9:206-213.
4. Baulieu EE (1996) Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 81:3147-3151.
5. Biggio G and Purdy RH (2001) Neurosteroids and brain function, in International Review of Neurobiology (Bradley RJ, Harris RA, and Jenner P eds) vol 46, pp 1-32, Academic Press, San Diego.
6. Cisternino S, Mercier C, Bourasset F, Roux F, and Scherrmann JM (2004) Expression, up-regulation and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301.
7. Cisternino S, Rousselle C, Dagenais C, and Scherrmann JM (2001) Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. Pharm Res (NY) 18:183-190.
8. Cooray HC, Blackmore CG, Maskell L, and Barrand MA (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13:2059-2063.
9. Corpechot C, Robel P, Axelson M, Sjovall J, and Baulieu EE (1981) Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci USA 78:4704-4707.
10. Dagenais C, Ducharme J, and Pollack GM (2001) Uptake and efflux of the peptidic delta-opioid receptor agonist [D-penicillamine2,5]-enkephalin at the murine blood-brain barrier by in situ perfusion. Neurosci Lett 301:155-158.
11. Dagenais C, Rousselle C, Pollack GM, and Scherrmann JM (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381-386.
12. Dallaire L, Tremblay L, and Beliveau R (1991) Purification and characterization of metabolically active capillaries of the blood-brain barrier. Biochem J 276:745-752.
13. Eisenblatter T and Galla HJ (2002) A new multidrug resistance protein at the blood-brain barrier. Biochem Biophys Res Commun 293:1273-1278.
14. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, and Borst P (2000) Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 83:366-374.
15. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, and Meier PJ (2000) Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294:73-79.
16. Gao B, Stieger B, Noe B, Fritschy JM, and Meier PJ (1999) Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1264.
17. Hagenbuch B and Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1-18.
18. Hasegawa M, Kusuhara H, Endou H, and Sugiyama Y (2003) Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J Pharmacol Exp Ther 305:1087-1097.
19. Hyafil F, Vergely C, Du Vignaud P, and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.
20. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649-15654.
21. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
22. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, and Schellens JH (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943-2950.
23. Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, and Paumgartner G (1998) Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett 424:173-176.
24. Kusuhara H and Sugiyama Y (2001) Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part 1). Drug Discov Today 6:150-156.
25. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, et al. (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621.
26. Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, Skurk C, Summer R, Fine A, Quesenberry PJ, and Walsh K (2003) Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 278:39068-39075.
27. Murakami H, Takanaga H, Matsuo H, Ohtani H, and Sawada Y (2000) Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am J Physiol Heart Circ Physiol 279:H1022-H1028.
28. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
29. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 97:2517-2524.
30. Schumacher M, Guennoun R, Robel P, and Baulieu EE (1997) Neurosteroids in the hippocampus: neuronal plasticity and memory. Stress 2:65-78.
31. Stoffel-Wagner B (2001) Neurosteroid metabolism in the human brain. Eur J Endocrinol 145:669-679.
32. Sun H, Dai H, Shaik N, and Elmquist WF (2003) Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55:83-105.
33. Suzuki M, Suzuki H, Sugimoto Y, and Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644-22649.
34. Takasato Y, Rapoport SI, and Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247:H484-H493.
35. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13:595-603.
36. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, and Schinkel AH (2003) The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine. Cancer Res 63:6447-6452.
37. Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A, Schumacher M, Delacourte A, Baulieu EE, and Akwa Y (2002) Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab 87:5138-5143.
38. Zelcer N, Reid G, Wielinga P, Kuil A, Van Der Heijden I, Schuetz JD, and Borst P (2003) Steroid- and bile acid-conjugates are substrates of human MRP4 (ABCC4). Biochem J 371:361-367.
39. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, and Stanimirovic DB (2003) Expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 17:2085-2087.
40. Zhang Y, Han H, Elmquist WF, and Miller DW (2000) Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 876:148-153.